The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pneumococcal Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Synopsis
The global Pneumococcal Vaccine market size was US$ 7358 million in 2024 and is forecast to a readjusted size of US$ 7935 million by 2031 with a CAGR of 1.1% during the forecast period 2025-2031.
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
The global Pneumococcal Vaccine market is strategically segmented by company, region (country), by Type, and by End User. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by End User for 2020-2031.
Market Segmentation
By Company:
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
By Type: (Dominant Segment vs High-Margin Innovation)
PPSV 23
PCV 7/13
PCV 10
By Application: (Core Demand Driver vs Emerging Opportunity)
Child
Adult
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Pfizer in Europe)
- Emerging Product Trends: PPSV 23 adoption vs. PCV 7/13 premiumization
- Demand-Side Dynamics: Child growth in China vs. Adult potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
India
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Pneumococcal Vaccine market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., PCV 7/13 in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Adult in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., PPSV 23 dominance in Europe vs. PCV 7/13 demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
The global Pneumococcal Vaccine market size was US$ 7358 million in 2024 and is forecast to a readjusted size of US$ 7935 million by 2031 with a CAGR of 1.1% during the forecast period 2025-2031.
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
The global Pneumococcal Vaccine market is strategically segmented by company, region (country), by Type, and by End User. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by End User for 2020-2031.
Market Segmentation
By Company:
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
By Type: (Dominant Segment vs High-Margin Innovation)
PPSV 23
PCV 7/13
PCV 10
By Application: (Core Demand Driver vs Emerging Opportunity)
Child
Adult
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Pfizer in Europe)
- Emerging Product Trends: PPSV 23 adoption vs. PCV 7/13 premiumization
- Demand-Side Dynamics: Child growth in China vs. Adult potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
India
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Pneumococcal Vaccine market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., PCV 7/13 in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Adult in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., PPSV 23 dominance in Europe vs. PCV 7/13 demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
Index1 Market Overview
1.1 Pneumococcal Vaccine Product Scope
1.2 Pneumococcal Vaccine by Type
1.2.1 Global Pneumococcal Vaccine Sales by Type (2020 & 2024 & 2031)
1.2.2 PPSV 23
1.2.3 PCV 7/13
1.2.4 PCV 10
1.3 Pneumococcal Vaccine by End User
1.3.1 Global Pneumococcal Vaccine Sales Comparison by End User (2020 & 2024 & 2031)
1.3.2 Child
1.3.3 Adult
1.4 Global Pneumococcal Vaccine Market Estimates and Forecasts (2020-2031)
1.4.1 Global Pneumococcal Vaccine Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Pneumococcal Vaccine Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Pneumococcal Vaccine Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Pneumococcal Vaccine Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Pneumococcal Vaccine Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Pneumococcal Vaccine Sales Market Share by Region (2020-2025)
2.2.2 Global Pneumococcal Vaccine Revenue Market Share by Region (2020-2025)
2.3 Global Pneumococcal Vaccine Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Pneumococcal Vaccine Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Pneumococcal Vaccine Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Pneumococcal Vaccine Market Size and Prospective (2020-2031)
2.4.2 Europe Pneumococcal Vaccine Market Size and Prospective (2020-2031)
2.4.3 China Pneumococcal Vaccine Market Size and Prospective (2020-2031)
2.4.4 Japan Pneumococcal Vaccine Market Size and Prospective (2020-2031)
2.4.5 India Pneumococcal Vaccine Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Pneumococcal Vaccine Historic Market Review by Type (2020-2025)
3.1.1 Global Pneumococcal Vaccine Sales by Type (2020-2025)
3.1.2 Global Pneumococcal Vaccine Revenue by Type (2020-2025)
3.1.3 Global Pneumococcal Vaccine Price by Type (2020-2025)
3.2 Global Pneumococcal Vaccine Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Pneumococcal Vaccine Sales Forecast by Type (2026-2031)
3.2.2 Global Pneumococcal Vaccine Revenue Forecast by Type (2026-2031)
3.2.3 Global Pneumococcal Vaccine Price Forecast by Type (2026-2031)
3.3 Different Types Pneumococcal Vaccine Representative Players
4 Global Market Size by End User
4.1 Global Pneumococcal Vaccine Historic Market Review by End User (2020-2025)
4.1.1 Global Pneumococcal Vaccine Sales by End User (2020-2025)
4.1.2 Global Pneumococcal Vaccine Revenue by End User (2020-2025)
4.1.3 Global Pneumococcal Vaccine Price by End User (2020-2025)
4.2 Global Pneumococcal Vaccine Market Estimates and Forecasts by End User (2026-2031)
4.2.1 Global Pneumococcal Vaccine Sales Forecast by End User (2026-2031)
4.2.2 Global Pneumococcal Vaccine Revenue Forecast by End User (2026-2031)
4.2.3 Global Pneumococcal Vaccine Price Forecast by End User (2026-2031)
4.3 New Sources of Growth in Pneumococcal Vaccine Application
5 Competition Landscape by Players
5.1 Global Pneumococcal Vaccine Sales by Players (2020-2025)
5.2 Global Top Pneumococcal Vaccine Players by Revenue (2020-2025)
5.3 Global Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pneumococcal Vaccine as of 2024)
5.4 Global Pneumococcal Vaccine Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Pneumococcal Vaccine, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Pneumococcal Vaccine, Product Type & Application
5.7 Global Key Manufacturers of Pneumococcal Vaccine, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Pneumococcal Vaccine Sales by Company
6.1.1.1 North America Pneumococcal Vaccine Sales by Company (2020-2025)
6.1.1.2 North America Pneumococcal Vaccine Revenue by Company (2020-2025)
6.1.2 North America Pneumococcal Vaccine Sales Breakdown by Type (2020-2025)
6.1.3 North America Pneumococcal Vaccine Sales Breakdown by End User (2020-2025)
6.1.4 North America Pneumococcal Vaccine Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Pneumococcal Vaccine Sales by Company
6.2.1.1 Europe Pneumococcal Vaccine Sales by Company (2020-2025)
6.2.1.2 Europe Pneumococcal Vaccine Revenue by Company (2020-2025)
6.2.2 Europe Pneumococcal Vaccine Sales Breakdown by Type (2020-2025)
6.2.3 Europe Pneumococcal Vaccine Sales Breakdown by End User (2020-2025)
6.2.4 Europe Pneumococcal Vaccine Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Pneumococcal Vaccine Sales by Company
6.3.1.1 China Pneumococcal Vaccine Sales by Company (2020-2025)
6.3.1.2 China Pneumococcal Vaccine Revenue by Company (2020-2025)
6.3.2 China Pneumococcal Vaccine Sales Breakdown by Type (2020-2025)
6.3.3 China Pneumococcal Vaccine Sales Breakdown by End User (2020-2025)
6.3.4 China Pneumococcal Vaccine Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Pneumococcal Vaccine Sales by Company
6.4.1.1 Japan Pneumococcal Vaccine Sales by Company (2020-2025)
6.4.1.2 Japan Pneumococcal Vaccine Revenue by Company (2020-2025)
6.4.2 Japan Pneumococcal Vaccine Sales Breakdown by Type (2020-2025)
6.4.3 Japan Pneumococcal Vaccine Sales Breakdown by End User (2020-2025)
6.4.4 Japan Pneumococcal Vaccine Major Customer
6.4.5 Japan Market Trend and Opportunities
6.5 India Market: Players, Segments, Downstream and Major Customers
6.5.1 India Pneumococcal Vaccine Sales by Company
6.5.1.1 India Pneumococcal Vaccine Sales by Company (2020-2025)
6.5.1.2 India Pneumococcal Vaccine Revenue by Company (2020-2025)
6.5.2 India Pneumococcal Vaccine Sales Breakdown by Type (2020-2025)
6.5.3 India Pneumococcal Vaccine Sales Breakdown by End User (2020-2025)
6.5.4 India Pneumococcal Vaccine Major Customer
6.5.5 India Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Pfizer Pneumococcal Vaccine Products Offered
7.1.5 Pfizer Recent Development
7.2 GSK
7.2.1 GSK Company Information
7.2.2 GSK Business Overview
7.2.3 GSK Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.2.4 GSK Pneumococcal Vaccine Products Offered
7.2.5 GSK Recent Development
7.3 MSD
7.3.1 MSD Company Information
7.3.2 MSD Business Overview
7.3.3 MSD Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.3.4 MSD Pneumococcal Vaccine Products Offered
7.3.5 MSD Recent Development
7.4 Sanofipasteur
7.4.1 Sanofipasteur Company Information
7.4.2 Sanofipasteur Business Overview
7.4.3 Sanofipasteur Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Sanofipasteur Pneumococcal Vaccine Products Offered
7.4.5 Sanofipasteur Recent Development
7.5 CDIBP
7.5.1 CDIBP Company Information
7.5.2 CDIBP Business Overview
7.5.3 CDIBP Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.5.4 CDIBP Pneumococcal Vaccine Products Offered
7.5.5 CDIBP Recent Development
8 Pneumococcal Vaccine Manufacturing Cost Analysis
8.1 Pneumococcal Vaccine Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Pneumococcal Vaccine
8.4 Pneumococcal Vaccine Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Pneumococcal Vaccine Distributors List
9.3 Pneumococcal Vaccine Customers
10 Pneumococcal Vaccine Market Dynamics
10.1 Pneumococcal Vaccine Industry Trends
10.2 Pneumococcal Vaccine Market Drivers
10.3 Pneumococcal Vaccine Market Challenges
10.4 Pneumococcal Vaccine Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Pneumococcal Vaccine Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Pneumococcal Vaccine Sales (US$ Million) Comparison by End User (2020 & 2024 & 2031)
Table 3. Global Market Pneumococcal Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Pneumococcal Vaccine Sales (K Doses) by Region (2020-2025)
Table 5. Global Pneumococcal Vaccine Sales Market Share by Region (2020-2025)
Table 6. Global Pneumococcal Vaccine Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Pneumococcal Vaccine Revenue Share by Region (2020-2025)
Table 8. Global Pneumococcal Vaccine Sales (K Doses) Forecast by Region (2026-2031)
Table 9. Global Pneumococcal Vaccine Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Pneumococcal Vaccine Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Pneumococcal Vaccine Revenue Share Forecast by Region (2026-2031)
Table 12. Global Pneumococcal Vaccine Sales by Type (K Doses) & (2020-2025)
Table 13. Global Pneumococcal Vaccine Sales Share by Type (2020-2025)
Table 14. Global Pneumococcal Vaccine Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Pneumococcal Vaccine Price by Type (USD/Dose) & (2020-2025)
Table 16. Global Pneumococcal Vaccine Sales by Type (K Doses) & (2026-2031)
Table 17. Global Pneumococcal Vaccine Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Pneumococcal Vaccine Price by Type (USD/Dose) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Pneumococcal Vaccine Sales by End User (K Doses) & (2020-2025)
Table 21. Global Pneumococcal Vaccine Sales Share by End User (2020-2025)
Table 22. Global Pneumococcal Vaccine Revenue by End User (US$ Million) & (2020-2025)
Table 23. Global Pneumococcal Vaccine Price by End User (USD/Dose) & (2020-2025)
Table 24. Global Pneumococcal Vaccine Sales by End User (K Doses) & (2026-2031)
Table 25. Global Pneumococcal Vaccine Revenue Market Share by End User (US$ Million) & (2026-2031)
Table 26. Global Pneumococcal Vaccine Price by End User (USD/Dose) & (2026-2031)
Table 27. New Sources of Growth in Pneumococcal Vaccine Application
Table 28. Global Pneumococcal Vaccine Sales by Company (K Doses) & (2020-2025)
Table 29. Global Pneumococcal Vaccine Sales Share by Company (2020-2025)
Table 30. Global Pneumococcal Vaccine Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Pneumococcal Vaccine Revenue Share by Company (2020-2025)
Table 32. Global Pneumococcal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pneumococcal Vaccine as of 2024)
Table 33. Global Market Pneumococcal Vaccine Average Price by Company (USD/Dose) & (2020-2025)
Table 34. Global Key Manufacturers of Pneumococcal Vaccine, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Pneumococcal Vaccine, Product Type & Application
Table 36. Global Key Manufacturers of Pneumococcal Vaccine, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Pneumococcal Vaccine Sales by Company (2020-2025) & (K Doses)
Table 39. North America Pneumococcal Vaccine Sales Market Share by Company (2020-2025)
Table 40. North America Pneumococcal Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Pneumococcal Vaccine Revenue Market Share by Company (2020-2025)
Table 42. North America Pneumococcal Vaccine Sales by Type (2020-2025) & (K Doses)
Table 43. North America Pneumococcal Vaccine Sales Market Share by Type (2020-2025)
Table 44. North America Pneumococcal Vaccine Sales by End User (2020-2025) & (K Doses)
Table 45. North America Pneumococcal Vaccine Sales Market Share by End User (2020-2025)
Table 46. Europe Pneumococcal Vaccine Sales by Company (2020-2025) & (K Doses)
Table 47. Europe Pneumococcal Vaccine Sales Market Share by Company (2020-2025)
Table 48. Europe Pneumococcal Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Pneumococcal Vaccine Revenue Market Share by Company (2020-2025)
Table 50. Europe Pneumococcal Vaccine Sales by Type (2020-2025) & (K Doses)
Table 51. Europe Pneumococcal Vaccine Sales Market Share by Type (2020-2025)
Table 52. Europe Pneumococcal Vaccine Sales by End User (2020-2025) & (K Doses)
Table 53. Europe Pneumococcal Vaccine Sales Market Share by End User (2020-2025)
Table 54. China Pneumococcal Vaccine Sales by Company (2020-2025) & (K Doses)
Table 55. China Pneumococcal Vaccine Sales Market Share by Company (2020-2025)
Table 56. China Pneumococcal Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Pneumococcal Vaccine Revenue Market Share by Company (2020-2025)
Table 58. China Pneumococcal Vaccine Sales by Type (2020-2025) & (K Doses)
Table 59. China Pneumococcal Vaccine Sales Market Share by Type (2020-2025)
Table 60. China Pneumococcal Vaccine Sales by End User (2020-2025) & (K Doses)
Table 61. China Pneumococcal Vaccine Sales Market Share by End User (2020-2025)
Table 62. Japan Pneumococcal Vaccine Sales by Company (2020-2025) & (K Doses)
Table 63. Japan Pneumococcal Vaccine Sales Market Share by Company (2020-2025)
Table 64. Japan Pneumococcal Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Pneumococcal Vaccine Revenue Market Share by Company (2020-2025)
Table 66. Japan Pneumococcal Vaccine Sales by Type (2020-2025) & (K Doses)
Table 67. Japan Pneumococcal Vaccine Sales Market Share by Type (2020-2025)
Table 68. Japan Pneumococcal Vaccine Sales by End User (2020-2025) & (K Doses)
Table 69. Japan Pneumococcal Vaccine Sales Market Share by End User (2020-2025)
Table 70. India Pneumococcal Vaccine Sales by Company (2020-2025) & (K Doses)
Table 71. India Pneumococcal Vaccine Sales Market Share by Company (2020-2025)
Table 72. India Pneumococcal Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 73. India Pneumococcal Vaccine Revenue Market Share by Company (2020-2025)
Table 74. India Pneumococcal Vaccine Sales by Type (2020-2025) & (K Doses)
Table 75. India Pneumococcal Vaccine Sales Market Share by Type (2020-2025)
Table 76. India Pneumococcal Vaccine Sales by End User (2020-2025) & (K Doses)
Table 77. India Pneumococcal Vaccine Sales Market Share by End User (2020-2025)
Table 78. Pfizer Company Information
Table 79. Pfizer Description and Business Overview
Table 80. Pfizer Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. Pfizer Pneumococcal Vaccine Product
Table 82. Pfizer Recent Development
Table 83. GSK Company Information
Table 84. GSK Description and Business Overview
Table 85. GSK Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. GSK Pneumococcal Vaccine Product
Table 87. GSK Recent Development
Table 88. MSD Company Information
Table 89. MSD Description and Business Overview
Table 90. MSD Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. MSD Pneumococcal Vaccine Product
Table 92. MSD Recent Development
Table 93. Sanofipasteur Company Information
Table 94. Sanofipasteur Description and Business Overview
Table 95. Sanofipasteur Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. Sanofipasteur Pneumococcal Vaccine Product
Table 97. Sanofipasteur Recent Development
Table 98. CDIBP Company Information
Table 99. CDIBP Description and Business Overview
Table 100. CDIBP Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. CDIBP Pneumococcal Vaccine Product
Table 102. CDIBP Recent Development
Table 103. Production Base and Market Concentration Rate of Raw Material
Table 104. Key Suppliers of Raw Materials
Table 105. Pneumococcal Vaccine Distributors List
Table 106. Pneumococcal Vaccine Customers List
Table 107. Pneumococcal Vaccine Market Trends
Table 108. Pneumococcal Vaccine Market Drivers
Table 109. Pneumococcal Vaccine Market Challenges
Table 110. Pneumococcal Vaccine Market Restraints
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Pneumococcal Vaccine Product Picture
Figure 2. Global Pneumococcal Vaccine Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Pneumococcal Vaccine Sales Market Share by Type in 2024 & 2031
Figure 4. PPSV 23 Product Picture
Figure 5. PCV 7/13 Product Picture
Figure 6. PCV 10 Product Picture
Figure 7. Global Pneumococcal Vaccine Sales (US$ Million) by End User (2020 & 2024 & 2031)
Figure 8. Global Pneumococcal Vaccine Sales Market Share by End User in 2024 & 2031
Figure 9. Child Examples
Figure 10. Adult Examples
Figure 11. Global Pneumococcal Vaccine Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Pneumococcal Vaccine Sales Growth Rate (2020-2031) & (US$ Million)
Figure 13. Global Pneumococcal Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 14. Global Pneumococcal Vaccine Price Trends Growth Rate (2020-2031) & (USD/Dose)
Figure 15. Pneumococcal Vaccine Report Years Considered
Figure 16. Global Market Pneumococcal Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 17. Global Pneumococcal Vaccine Revenue Market Share by Region: 2020 VS 2024
Figure 18. North America Pneumococcal Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. North America Pneumococcal Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 20. Europe Pneumococcal Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 21. Europe Pneumococcal Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 22. China Pneumococcal Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 23. China Pneumococcal Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 24. Japan Pneumococcal Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 25. Japan Pneumococcal Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 26. India Pneumococcal Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 27. India Pneumococcal Vaccine Sales (K Doses) Growth Rate (2020-2031)
Figure 28. Global Pneumococcal Vaccine Revenue Share by Type (2020-2025)
Figure 29. Global Pneumococcal Vaccine Sales Share by Type (2026-2031)
Figure 30. Global Pneumococcal Vaccine Revenue Share by Type (2026-2031)
Figure 31. Global Pneumococcal Vaccine Revenue Share by End User (2020-2025)
Figure 32. Global Pneumococcal Vaccine Revenue Growth Rate by End User in 2020 & 2024
Figure 33. Global Pneumococcal Vaccine Sales Share by End User (2026-2031)
Figure 34. Global Pneumococcal Vaccine Revenue Share by End User (2026-2031)
Figure 35. Global Pneumococcal Vaccine Sales Share by Company (2024)
Figure 36. Global Pneumococcal Vaccine Revenue Share by Company (2024)
Figure 37. Global 5 Largest Pneumococcal Vaccine Players Market Share by Revenue in Pneumococcal Vaccine: 2020 & 2024
Figure 38. Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 39. Manufacturing Cost Structure of Pneumococcal Vaccine
Figure 40. Manufacturing Process Analysis of Pneumococcal Vaccine
Figure 41. Pneumococcal Vaccine Industrial Chain
Figure 42. Channels of Distribution (Direct Vs Distribution)
Figure 43. Distributors Profiles
Figure 44. Bottom-up and Top-down Approaches for This Report
Figure 45. Data Triangulation
Figure 46. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
